CN Patent

CN118903386A — Glp-1组合物及其用途

Assigned to Novo Nordisk AS · Expires 2024-11-08 · 2y expired

What this patent protects

本发明涉及包含不超过0.01％(w/w)的苯酚的GLP‑1肽司美鲁肽的药物组合物、其制备、包含这类组合物的药盒及其用途。

USPTO Abstract

本发明涉及包含不超过0.01％(w/w)的苯酚的GLP‑1肽司美鲁肽的药物组合物、其制备、包含这类组合物的药盒及其用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN118903386A
Jurisdiction
CN
Classification
—
Expires
2024-11-08
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.